Population pharmacokinetics of Rilpivirine in HIV-1-infected patients treated with the single-tablet regimen rilpivirine/tenofovir/emtricitabine

Population Pharmacokinetics and Pharmacogenetics Analysis of Rilpivirine in HIV-1-Infected Individuals

(2016) Manel Aouri et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Impact of Food and Different Meal Types on the Pharmacokinetics of Rilpivirine

(2013) Herta M. Crauwels et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Fundamentals of Population Pharmacokinetic Modelling

(2012) Catherine M. T. Sherwin et al.   CLINICAL PHARMACOKINETICS

Effect of gender and race on the week 48 findings in treatment-naïve, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVE

(2012) S Hodder et al.   HIV MEDICINE

Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor

(2012) M. Sharma et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial

(2011) Calvin J Cohen et al.   LANCET

Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial

(2011) Jean-Michel Molina et al.   LANCET

Effect of intrinsic and extrinsic factors on the pharmacokinetics of TMC278 in antiretroviral-naïve, HIV-1-infected patients in ECHO and THRIVE

(2010) HM Crauwels et al.   Journal of the International AIDS Society

Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and Solutions

(2009) Radojka M. Savic et al.   AAPS Journal

Mechanism-Based Concepts of Size and Maturity in Pharmacokinetics

(2007) B.J. Anderson et al.   Annual Review of Pharmacology and Toxicology